fda compounding semaglutide enforcement 2025 news February 17, 2026: Pennsylvania pharmacy earns another warning letter – Partnership for Safe Medicines What Patients Need to Know

Because GLP1 agonists are becoming more widely used, scientists are now studying an important question: How do these medications affect eye health

Tirzepatide tends to produce greater weight loss on average (20.9% in SURMOUNT-1 versus 14.9% in STEP 1), which may translate to slightly more pronounced menstrual effects

Research has explored its potential influence on: Appetite and hunger regulation Energy expenditure and metabolic rate Glucose and insulin signaling Fat metabolism and body composition Weight management pathways

O papel do farmacutico no manejo da obesidade Suaiden ressalta que o tratamento da obesidade deve ser conduzido por profissionais de sade qualificados, incluindo os farmacuticos